FDA backs PureTech's phase 3 move for IPF drug deupirfenidone
(Alliance News) - PureTech Health PLC on Monday said its idiopathic pulmonary fibrosis drug candidate deupirfenidone has cleared a key regulatory milestone, with the US Food & Drug Administration backing progression into a pivotal phase 3 trial planned for the first half of 2026. Read More